<DOC>
	<DOCNO>NCT01945268</DOCNO>
	<brief_summary>A multi-centre , randomize , placebo control , trial . Participants high-risk vascular event network INTER- CHF randomize inactivated influenza vaccine placebo follow prospectively three influenza season . 600 participant enrol prior influenza season randomize either influenza vaccine saline placebo .</brief_summary>
	<brief_title>Influenza Vaccine To Prevent Adverse Vascular Events : Pilot</brief_title>
	<detailed_description>Cardiovascular disease major cause morbidity mortality . There recent evidence infection due influenza may precipitate vascular event myocardial infarction stroke . There evidence influenza vaccination may prevent event data inconclusive . The investigator propose randomize controlled trial ass whether influenza vaccination prevent vascular illness . Adults clinical heart failure randomize inactivated influenza vaccine saline placebo . This pilot study provide need data establish feasibility large study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 18 year NYHA functional class II , III IV Anaphylactic reaction previous dose TIV Known IgEmediated hypersensitivity egg manifest hive , swell mouth throat , difficulty breathing , hypotension , shock GuillainBarré syndrome within eight week previous influenza vaccine Anaphylactic reaction neomycin Patients influenza vaccine two three previous year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>vascular , influenza , vaccine , heart failure</keyword>
</DOC>